Cierra raises $21m for catheter-based heart-treatment to reduce migraine:
This article was originally published in Clinica
Executive Summary
Cierra, which is developing a catheter system to treat the heart defect, patent foramen ovale (PFO), has raised $21m from venture investors led by Delphi Ventures. A PFO is a valve-like opening between the left and right atria, which studies have linked to migraine headaches. The Redwood, California company will use the funds to begin US clinical trials and commercialise its PFX non-implant-based system to close the hole with a view to reducing migraine in sufferers. Other companies offering implant-based closure of PFO include NMT Medical (Boston, Massachusetts) and AGA Medical (Golden Valley, Minnesota).